Rapport reports positive Phase 1 RAP-219 data; CMO steps down

Rapport Therapeutics, Inc.

PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.
MAD-2 trial: no sedation or motoric impairment observed; all adverse events Grade 1 or 2.
Phase 2a focal epilepsy trial on track; topline data expected mid-2025.
Bradley Galer, M.D., stepped down as Chief Medical Officer; search for successor underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.